Pharmaron vs WuXi Biologics: CDMO Comparison

How does Pharmaron compare to WuXi Biologics for AAV manufacturing?

As of Nov 2026, Pharmaron: 5 FDA inspections (including 4 NAI, 1 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 86.9. WuXi Biologics: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 82.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Pharmaron and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score
87/100
Quality (FDA + GMP)
100/100
FDA inspections
5
— NAI / VAI / OAI
4 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Available
Modalities
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Shanghai, CN · Wuxi, CN
Signal Score
83/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
—
Modalities
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody

Key differences

  • Pharmaron has more FDA inspections on record (5 vs 1) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • WuXi Biologics holds 3 active EMA GMP certificates; Pharmaron does not appear in EudraGMDP.

On a 13-modality CDMO landscape, both Pharmaron and WuXi Biologics qualify as AAV manufacturers; Pharmaron carries the higher composite Signal Score for AAV programs in this comparison.

What to evaluate for AAV programs

Both Pharmaron and WuXi Biologics qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

See all AAV CDMOs ranked by Signal Score →

Frequently asked: Pharmaron vs WuXi Biologics

How does Pharmaron compare to WuXi Biologics for AAV manufacturing?

On CDMO Signal's composite Signal Score, Pharmaron is 87/100 and WuXi Biologics is 83/100; Pharmaron has 5 FDA inspections on record vs 1 for WuXi Biologics; European coverage is 1 active EMA+MHRA certificate for Pharmaron vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Pharmaron or WuXi Biologics?

Both Pharmaron and WuXi Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Pharmaron has 5 FDA inspections on record; WuXi Biologics has 1.

How do Pharmaron and WuXi Biologics compare on European GMP coverage?

Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for AAV manufacturing — Pharmaron or WuXi Biologics?

Both Pharmaron and WuXi Biologics are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Pharmaron carries a Signal Score of 87/100 and WuXi Biologics carries 83/100 — essentially tied for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Pharmaron and WuXi Biologics for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.